Therapeutic inhibition of matrix metalloproteinases for the treatment of chronic obstructive pulmonary disease (COPD)

Current Medical Research and Opinion

Volumn 21, Issue 4, 2005, Pages 587-593

  Daheshia, Massoud ^a,b  

^a UNIVERSITY OF NEW MEXICO SCHOOL OF MEDICINE   (United States)

^b LOVELACE RESPIRATORY RESEARCH INSTITUTE   (United States)

Author keywords

COPD; Inhibitor; Lung inflammation; Matrix metalloproteinases; Selectivity

Indexed keywords

BATIMASTAT; CGS 27023A; MARIMASTAT; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; PRINOMASTAT; TISSUE INHIBITOR OF METALLOPROTEINASE; TOXIC GAS;

AIRWAY; CAUSE OF DEATH; CHRONIC OBSTRUCTIVE LUNG DISEASE; CIGARETTE SMOKING; CLINICAL TRIAL; DRUG SELECTIVITY; DRUG SPECIFICITY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; LUNG ALVEOLUS WALL; LUNG INSUFFICIENCY; PARTICULATE MATTER; PATHOPHYSIOLOGY; RESPIRATORY AIRFLOW; REVIEW; RISK FACTOR; SIDE EFFECT; UNITED STATES;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; HUMANS; MATRIX METALLOPROTEINASES; MICE; POLYMORPHISM, GENETIC; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 18744384999     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079905X41417     Document Type: Review

References (56)

1. Sutherland ER, Cherniack RM. Management of chronic obstructive pulmonary disease. N Engl J Med 2004;350(26):2689-97
2. Fabbri LM, Hurd SS, GOLD Scientific Committee. Global Strategy for the Diagnosis, Management and Prevention of COPD: 2003 update. Eur Respir J 2003;22(1):1-2
3. Barnes PJ. New treatments for COPD. Nat Rev Drug Discov 2002;1(6):437-46
4. Cross S. The worldwide burden of COPD is on the increase. Br J Nurs 2004;13(18):1066
5. Chen Y. Genetics and pulmonary medicine. 10: Genetic epidemiology of pulmonary function. Thorax 1999;54(9):818-24
6. Snider GL. Chronic obstructive pulmonary disease: a definition and implications of structural determinants of airflow obstruction for epidemiology. Am Rev Respir Dis 1989;140(3 Pt 2):S3-8
7. Pauwels RA, Buist AS, Calverley PM, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. Am J Respir Crit Care Med 2001;163(5):1256-76
8. Shapiro SD. Proteinases in chronic obstructive pulmonary disease. Biochem Soc Trans 2002;30(2):98-102
9. Matter H, Schudok M. Recent advances in the design of matrix metalloprotease inhibitors. Curr Opin Drug Discov Devel 2004;7(4):513-35
10. Parks WC, Wilson CL, Lopez-Boado YS. Matrix metalloproteinases as modulators of inflammation and innate immunity. Nat Rev Immunol 2004 Aug;4(8):617-29
11. Strongin AY, Collier I, Bannikov G, et al. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem 1995;270(10):5331-8
12. Nelson KK, Melendez JA. Mitochondrial redox control of matrix metalloproteinases. Free Radic Biol Med 2004;37(6):768-84
13. Parks WC, Lopez-Boado YS, Wilson CL. Matrilysin in epithelial repair and defense. Chest 2001;120(1 Suppl):36S-41S
14. Johnson PR. Role of human airway smooth muscle in altered extracellular matrix production in asthma. Clin Exp Pharmacol Physiol 2001;28(3):233-6
15. Foda HD, George S, Rollo E, et al. Regulation of gelatinases in human airway smooth muscle cells: mechanism of progelatinase A activation. Am J Physiol 1999;277(1 Pt 1):L174-821
16. Lopez-Boado YS, Wilson CL, Hooper LV, et al. Bacterial exposure induces and activates matrilysin in mucosal epithelial cells. J Cell Biol 2000;148(6):1305-15
17. Lopez-Boado YS, Wilson CL, Parks WC. Regulation of matrilysin expression in airway epithelial cells by Pseudomonas aeruginosa flagellin. J Biol Chem 2001;276(44):41417-23. Epub 2001 Aug 29
18. Yao PM, Delclaux C, d'Ortho MP et al. Cell-matrix interactions modulate 92-kD gelatinase expression by human bronchial epithelial cells. Am J Respir Cell Mol Biol 1998;18(6):813-22
19. Lim S, Roche N, Oliver BG, et al. Balance of matrix metalloprotease-9 and tissue inhibitor of metalloprotease-1 from alveolar macrophages in cigarette smokers. Regulation by interleukin-10. Am J Respir Crit Care Med 2000;162(4 Pt 1):1355-60
20. Dahlen B, Shute J, Howarth P. Immunohistochemical localisation of the matrix metalloproteinases MMP-3 and MMP-9 within the airways in asthma. Thorax 1999;54(7):590-6
21. Shapiro SD. Proteolysis in the lung. Eur Respir J Suppl 2003;44:30s-32s
22. Imai K, Dalal SS, Chen ES, et al. Human collagenase (matrix metalloproteinase-1) expression in the lungs of patients with emphysema. Am J Respir Crit Care Med 2001;163(3 Pt 1): 786-91
23. Ohnishi K, Takagi M, Kurokawa Y, et al. Matrix metalloproteinase-mediated extracellular matrix protein degradation in human pulmonary emphysema. Lab Invest 1998;78(9):1077-87
24. Betsuyaku T, Nishimura M, Takeyabu K, et al. Neutrophil granule proteins in bronchoalveolar lavage fluid from subjects with subclinical emphysema. Am J Respir Crit Care Med 1999;159(6):1985-91
25. Finlay GA, Russell KJ, McMahon KJ, et al. Elevated levels of matrix metalloproteinases in bronchoalveolar lavage fluid of emphysematous patients. Thorax 1997;52(6):502-6
26. Shapiro SD. Elastolytic metalloproteinases produced by human mononuclear phagocytes. Potential roles in destructive lung disease. Am J Respir Crit Care Med 1994;150(6 Pt 2):S160-4
27. Segura-Valdez L, Pardo A, Gaxiola M, et al. Upregulation of gelatinases A and B, collagenases 1 and 2, and increased parenchymal cell death in COPD. Chest 2000;117(3):684-94
28. Han Z, Junxu, Zhong N. Expression of matrix metalloproteinases MMP-9 within the airways in asthma. Respir Med 2003;97(5): 563-7
29. Betsuyaku T, Tanino M, Nagai K, et al. Extracellular matrix metalloproteinase inducer is increased in smokers' bronchoalveolar lavage fluid. Am J Respir Crit Care Med 2003;Jul 15;168(2):222-7. Epub 2003 Apr 24
30. Vignola AM, Riccobono L, Mirabella A, et al. Sputum metalloproteinase-9/ tissue inhibitor of metalloproteinase-1 ratio correlates with airflow obstruction in asthma and chronic bronchitis. Am J Respir Crit Care Med 1998;158(6):1945-50
31. Hitesh S, Deshmukh LM, Case SC, et al. Metalloproteinases mediate mucin 5AC expression by epidermal growth factor receptor activation. Am J Respir Crit Care Med 2005;171:305-14
32. Di Stefano A, Capelli A, Lusuardi M, et al. Severity of airflow limitation is associated with severity of airway inflammation in smokers. Am J Respir Crit Care Med 1998;158(4):1277-85
33. Tetley TD. Macrophages and the pathogenesis of COPD. Chest 2002;121(5 Suppl):156S-159S
34. Finlay GA, O'Driscoll LR, Russell KJ, et al. Matrix metalloproteinase expression and production by alveolar macrophages in emphysema. Am J Respir Crit Care Med 1997;156(1):240-7
35. Russell RE, Culpitt SV, DeMatos C, et al. Release and activity of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 by alveolar macrophages from patients with chronic obstructive pulmonary disease. Am J Respir Cell Mol Biol 2002;26(5):602-9
36. Russell RE, Thorley A, Culpitt SV, et al. Alveolar macrophage-mediated elastolysis: roles of matrix metalloproteinases, cysteine, and serine proteases. Am J Physiol Lung Cell Mol Physiol 2002;283(4):L867-73
37. Minematsu N, Nakamura H, Tateno H, et al. Genetic polymorphism in matrix metalloproteinase-9 and pulmonary emphysema. Biochem Biophys Res Commun 2001;289(1):116-9
38. Zhou M, Huang SG, Wan HY, et al. Genetic polymorphism in matrix metalloproteinase-9 and the susceptibility to chronic obstructive pulmonary disease in Han population of south China. Chin Med J (Engl) 2004;117(10):1481-4
39. Joos L, He JQ, Shepherdson MB, et al. The role of matrix metalloproteinase polymorphisms in the rate of decline in lung function. Hum Mol Genet 2002;11(5):569-76.
40. Erratum in: Hum Mol Genet 2003 Apr 1;12(7):803-4
41. Hirano K, Sakamoto T, Uchida Y, et al. Tissue inhibitor of metalloproteinases-2 gene polymorphisms in chronic obstructive pulmonary disease. Eur Respir J 2001;18(5):748-52
42. D'Armiento, Dalal SS, Okada Y, et al. Collagenase expression in the lungs of transgenic mice causes pulmonary emphysema. Cell 1992;71(6):955-61
43. Foronjy RF, Okada Y, Cole R, et al. Progressive adult-onset emphysema in transgenic mice expressing human MMP-1 in the lung. Am J Physiol Lung Cell Mol Physiol 2003;284(5):L727-37. Epub 2003 Jan 10
44. Lanone S, Zheng T, Zhu Z, et al. Overlapping and enzyme-specific contributions of matrix metalloproteinases-9 and -12 in IL-13-induced inflammation and remodeling. J Clin Invest 2002;110(4):463-74
45. Wang Z, Zheng T, Zhu Z, et al. Interferon gamma induction of pulmonary emphysema in the adult murine lung. J Exp Med 2000;192(11):1587-600
46. Hautamaki RD, Kobayashi DK, Senior RM, et al. Requirement for macrophage elastase for cigarette smoke-induced emphysema in mice. Science 1997;277(5334):2002-4
47. Churg A, Wang RD, Tai H, et al. Macrophage metalloelastase mediates acute cigarette smoke-induced inflammation via tumor necrosis factor-alpha release. Am J Respir Crit Care Med 2003;167(8):1083-9. Epub 2003 Jan 09
48. Morris DG, Huang X, Kaminski N, et al. Loss of integrin alpha(v)beta6-mediated TGF-beta activation causes Mmp12-dependent emphysema. Nature 2003;422(6928):169-73
49. Wert SE, Yoshida M, LeVine AM, et al. Increased metalloproteinase activity, oxidant production, and emphysema in surfactant protein D gene-inactivated mice. Proc Natl Acad Sci USA 2000;97(11):5972-7
50. Shapiro SD, Goldstein NM, Houghton AM, et al. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am J Pathol 2003;163(6):2329-35
51. Whelan CJ. Metalloprotease inhibitors as anti-inflammatory agents: an evolving target? Curr Opin Investig Drugs 2004;5(5):511-6
52. MacPherson LJ, Bayburt EK, Capparelli MP, et al. Discovery of CGS 27023A, a non-peptidic, potent, and orally active stromelysin inhibitor that blocks cartilage degradation in rabbits. J Med Chem 1997;40(16):2525-32
53. Coussens LM, Fingleton B, Matrisian LM. Matrix metalloproteinase inhibitors and cancer: trials and tribulations. Science 2002;295(5564):2387-92
54. Broker LE, Giaccone G. The role of new agents in the treatment of non-small cell lung cancer. Eur J Cancer 2002;38(18):2347-61
55. Hoekstra R, Eskens FA, Verweij J. Matrix metalloproteinase inhibitors: current developments and future perspectives. Oncologist 2001;6(5):415-27
56. Frankenberger M, Hauck RW, Frankenberger B, et al. All trans-retinoic acid selectively down-regulates matrix metalloproteinase-9 (MMP-9) and up-regulates tissue inhibitor of metalloproteinase-1 (TIMP-1) in human bronchoalveolar lavage cells. Mo Med 2001;7(4):263-70